Cipla Limited
CIPLA
Rankning i aktier
#1808
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Aktiekurs
$14.61
Senast synkroniserad: 2026-10-19
Marknadsvärde
$11.81B
Förändring (1 dag)
-0.11%
Förändring (1 år)
-21.65%
Land
IN
Handel Cipla Limited (CIPLA)
Kategori
Healthcare
Utdelningsavkastning för Cipla Limited (CIPLA)
Utdelningsavkastningen (TTM) för Cipla Limited (aktiesymbol: CIPLA) per 2024-03-31 är: 0.57%
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.50%
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.50%
Historik för utdelningsavkastning för Cipla Limited (CIPLA) från 2004 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
| År | Utdelningsavkastning | Ändra |
|---|---|---|
| 2026 (TTM) | 0.98% | 8.89% |
| 2025 | 0.90% | 57.89% |
| 2024 | 0.57% | 1.79% |
| 2023 | 0.56% | 14.29% |
| 2022 | 0.49% | 0.00% |
| 2021 | 0.00% | -100.00% |
| 2020 | 1.66% | 191.23% |
| 2019 | 0.57% | 62.86% |
| 2018 | 0.35% | 2.94% |
| 2017 | 0.34% | -12.82% |
| 2016 | 0.39% | 39.29% |
| 2015 | 0.28% | -46.15% |
| 2014 | 0.52% | 0.00% |
| 2013 | 0.52% | -21.21% |
| 2012 | 0.66% | -24.14% |
| 2011 | 0.87% | 50.00% |
| 2010 | 0.58% | -36.26% |
| 2009 | 0.91% | 0.00% |
| 2008 | 0.91% | 7.06% |
| 2007 | 0.85% | 60.38% |
| 2006 | 0.53% | -54.70% |
| 2005 | 1.17% | 37.65% |
| 2004 | 0.85% | 0.00% |
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter
| Företag | Utdelningsavkastning | Land |
|---|---|---|
| 0.00% |
DE
|
|
| 0.00% |
DE
|
|
| 0.00% |
JP
|
|
| 0.00% |
CH
|
|
| 0.91% |
IN
|
